Article
Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
Cancer medicine - 1 Dec 2021
Yang Yaning, Xu Haiyan, Ma Li, Yang Lu, Yang Guangjian, Zhang Shuyang, Ai Xin, Zhang Shucai, Wang Yan
Abstract excerpt
BACKGROUND: There was no standard treatment for patients who acquired resistance to osimertinib mediated by epidermal growth factor receptor (EGFR) T790M-cis-C797S. The aim of this study was to investigate the association between different therapeutic strategies and survival outcomes among these patients. METHODS: This retrospective cohort study analyzed 46 patients with metastatic lung adenocarcinoma and EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.